Difference between revisions of "Editorial Board"
Jump to navigation
Jump to search
Line 33: | Line 33: | ||
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gastrointestinal Oncology''' | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gastrointestinal Oncology''' | ||
|- | |- | ||
− | |rowspan=8 style="background-color:#F0F0F0"| | + | |rowspan=8 style="background-color:#F0F0F0"|[[File:nkv.jpg|thumb|upright=0.4|center]] |
− | |rowspan=8|<big>Neeta Venepalli, MD<br>Chicago, IL</big> | + | |rowspan=8|<big>Neeta K. Venepalli, MD<br>Chicago, IL</big> |
|style="background-color:#deebf7"|[[Anal cancer]] | |style="background-color:#deebf7"|[[Anal cancer]] | ||
|- | |- | ||
Line 53: | Line 53: | ||
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Genitourinary Oncology''' | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Genitourinary Oncology''' | ||
|- | |- | ||
− | |rowspan=5 style="background-color:#F0F0F0"| | + | |rowspan=5 style="background-color:#F0F0F0"|[[File:aymen_elfiky.jpg|thumb|upright=0.4|center]] |
|rowspan=5|<big>Aymen Elfiky, MD, MSc, MBA<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn] | |rowspan=5|<big>Aymen Elfiky, MD, MSc, MBA<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn] | ||
|style="background-color:#deebf7"|[[Bladder cancer]] | |style="background-color:#deebf7"|[[Bladder cancer]] | ||
Line 91: | Line 91: | ||
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Sarcoma''' | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Sarcoma''' | ||
|- | |- | ||
− | |rowspan=4 style="background-color:#F0F0F0"| | + | |rowspan=4 style="background-color:#F0F0F0"|[[File:jim_chen.jpeg|thumb|upright=0.4|center]] |
|rowspan=4|<big>James L. Chen, MD, MS<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn] | |rowspan=4|<big>James L. Chen, MD, MS<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn] | ||
|style="background-color:#deebf7"|[[Ewing's sarcoma]] | |style="background-color:#deebf7"|[[Ewing's sarcoma]] | ||
Line 117: | Line 117: | ||
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms''' | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms''' | ||
|- | |- | ||
− | |rowspan=7 style="background-color:#F0F0F0"| | + | |rowspan=7 style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|thumb|upright=0.4|center]] |
|rowspan=7|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big> | |rowspan=7|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big> | ||
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia]] | |style="background-color:#fee0d2"|[[Chronic myelogenous leukemia]] | ||
Line 154: | Line 154: | ||
|- | |- | ||
|style="background-color:#efedf5"|[[Graft versus host disease (GVHD)]] | |style="background-color:#efedf5"|[[Graft versus host disease (GVHD)]] | ||
+ | |- | ||
+ | !colspan="3" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Benign Hematology''' | ||
+ | |- | ||
+ | |rowspan=6 style="background-color:#F0F0F0"|[[File:Shruti.jpg|thumb|upright=0.4|center]] | ||
+ | |rowspan=6|<big>Shruti Chaturvedi, MD, MSCI<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn] | ||
+ | |style="background-color:#e5f5e0"|[[Aplastic anemia]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Autoimmune cytopenias]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Autoimmune thrombocytopenic purpura (ITP)]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Coagulopathies]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Cold agglutinin disease]] | ||
+ | |- | ||
+ | |rowspan=5 style="background-color:#F0F0F0"|[[File:Tillman_Benjamin-2.jpg|thumb|upright=0.4|center]] | ||
+ | |rowspan=5|<big>Benjamin Tillman, MD<br>Nashville, TN</big> | ||
+ | |style="background-color:#e5f5e0"|[[Hemophagocytic lymphohistiocytosis (HLH)]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Sickle cell anemia]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]] | ||
|- | |- | ||
|} | |} |
Revision as of 03:01, 5 October 2017
Please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
Peter C. Yang, MD Boston, MA Twitter: Hem_Onc |
Deputy Editor
Jeremy L. Warner, MD, MS Nashville, TN Twitter: Hemoncwarner |